Buprenorphine and Oxcarbazepine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Oxcarbazepine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You're taking buprenorphine (for pain or opioid dependence) along with oxcarbazepine (Trileptal). Oxcarbazepine can speed up the liver enzyme that breaks down buprenorphine. That means your body may clear the buprenorphine faster, leaving less of it working. The result can be weaker relief and possible opioid withdrawal symptoms, like feeling anxious, achy, sweaty, restless, or having stomach upset.
The good news is your care team can manage this. Please don't stop or change either medicine on your own. Instead, tell your doctor or pharmacist you take both so they can adjust your buprenorphine dose and watch how you're doing until things feel stable.
Effect: Oxcarbazepine, a CYP3A4 inducer, increases CYP3A4-mediated metabolism of buprenorphine, lowering buprenorphine plasma concentrations and exposure. This reduces buprenorphine efficacy and may precipitate opioid withdrawal.
- Direction: Reduced buprenorphine effect (neither drug is a prodrug requiring activation here).
- Severity/evidence: Major; substantiation probable. Onset unspecified.
- Management: If the inducer is needed, titrate buprenorphine up to stable effect and monitor for withdrawal. On inducer discontinuation, anticipate a dose reduction and monitor for respiratory depression. For subQ (Sublocade/Brixadi) patients, verify adequate levels; consider a transmucosal formulation allowing finer titration if fixed depot doses are inadequate.
What happens
Reduced buprenorphine exposure and reduced efficacy of buprenorphine
Interaction Deep Dive
Combining buprenorphine with a CYP3A4 inducer can precipitate opioid withdrawal symptoms because buprenorphine plasma concentrations are lowered. When a patient on buprenorphine must also receive a CYP3A4 inducer, one option is to raise the buprenorphine dose until stable drug effects are reached, while watching for signs of withdrawal. Conversely, if a CYP3A4 inducer is stopped in someone being treated with buprenorphine, a reduction in the buprenorphine dose should be considered, along with monitoring for respiratory depression2. Should dose adjustment prove impossible once the CYP3A4 inducer is removed, the patient should be switched back to a buprenorphine formulation that allows finer dose titration. For patients being changed over from transmucosal buprenorphine given together with CYP3A4 inducers, confirm through monitoring that subQ buprenorphine supplies an adequate plasma buprenorphine level. In those already receiving subQ buprenorphine who then need a CYP3A4 inducer, monitor for withdrawal. When the buprenorphine dose is insufficient while the concomitant medication is present, and that medication can neither be decreased nor withdrawn, modify the buprenorphine dose accordingly. If the available doses are inadequate to attain the target dose, use a buprenorphine formulation that supports more precise dose adjustments1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medications as prescribed unless your care team tells you otherwise. This combination can lower your buprenorphine levels, so your team will watch for signs it isn't working.
- Your buprenorphine dose may need to be adjusted and individualized by your care team, and they may monitor you more closely for withdrawal.
- If oxcarbazepine is later stopped, your buprenorphine dose may be lowered, since levels can rise again.
- With long-acting injectable buprenorphine, a switch to a form that allows finer dose changes may be considered.
Tell your pharmacist or prescriber if you notice withdrawal symptoms such as anxiety, sweating, nausea, or aches.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of a concurrently administered CYP3A4 inducer on buprenorphine exposure in patients receiving subQ buprenorphine has not been investigated; nevertheless, interactions of this kind have been demonstrated in studies employing transmucosal buprenorphine. Buprenorphine's effects may vary according to the route of administration 1.
Common questions
Can I take Buprenorphine and Oxcarbazepine together?
Oxcarbazepine can lower buprenorphine levels and weaken its effect, sometimes triggering withdrawal, so let your care team know you take both so they can adjust the dose and monitor you. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Oxcarbazepine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Oxcarbazepine interaction managed?
Keep taking both medications as prescribed unless your care team tells you otherwise. This combination can lower your buprenorphine levels, so your team will watch for signs it isn't working. Your buprenorphine dose may need to be adjusted and individualized by your care team, and they may monitor you more closely for withdrawal. If oxcarbazepine is later stopped, your buprenorphine dose may be lo… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Oxcarbazepine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Oxcarbazepine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist